Skip To Main Content
Axel Nelson on Muck Rack

Axel Nelson

As seen in: The BMJ, European Journal of Cancer, EJSO - European Journal of Surgical Oncology, Gig Harbor Now

Get in touch with Axel

Contact Axel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Axel Nelson’s Biography

Read Full Bio →

Articles

Gig Harbor Now and Then | Log pirates and brand identification

|
By Greg Spadoni, Axel Nelson
| Gig Harbor Now
Community The Gig Harbor Now and Then questions of local history on June 15 concerned the logging industry. In 1890, a law was passed requiring all logs transported in rafts on the waters of Washington west of the Cascade Mountains to be identified with the owner’s mark. The questions: Answer: A brand, struck into the thick end of the log. No doubt many readers already knew that, because Gertie Jackson has been advertising it on her whistle-stop reader board for over a month.
Open in Who Shared Issue with article?

Nodal localisation with magnetic seed in patients with stage III melanoma receiving neoadjuvant immune checkpoint inhibitors, a feasibility study

|
By Region Västra Götaland, Lars Ny, Anne E. Huibers, Fredrik Wärnberg, Ellen Krabbe, Axel Nelson, Roger Olofsson Bagge, Ellen Krabbe
| EJSO - European Journal of Surgical Oncology Verified
Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Balch, C.M. ... Final version of 2009 AJCC melanoma staging and classification J Clin Oncol. 2009; 27(36):6199-6206 2. Weber, J. ... Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma N Engl J Med. 2017; 377(19):1824-1835 3. Grossmann, K.F. ... Adjuvant Pembrolizumab versus IFNalpha2b or Ipilimumab in Resected High-Risk Melanoma Cancer Discov. 2022; 12(3):644-653 4. Eggermont, A.M.M. ∙ Robert, C.
Open in Who Shared Issue with article?

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: a retrospective cohort study

|
By Axel Nelson, Karl Björkström
| European Journal of Cancer Verified
Keywords Time of day Neoadjuvant treatment Immune checkpoint inhibitor PD-1 Surgery Melanoma Get full text access Log in, subscribe or purchase for full access. Data availability statement Data will be shared after a reasonable request to the corresponding author. References 1. Scheiermann, C. ∙ Gibbs, J. ∙ Ince, L. ... Clocking in to immunity Nat Rev Immunol. 2018; 18:423-437 2. Lichterman, J.N. ...
Open in Who Shared Issue with article?
See all 4 articles

Awards

International Consortium of Investigative Journalists Daniel Pearl Award

View Award